The SMA Market: Assessing The Unknowns
Treatment Progress Leads To New Challenges In Spinal Muscular Atrophy
The introductions of Spinraza and Zolgensma in SMA offer new insights into how to address neurodegenerative diseases. But more real world evidence is needed.
